Anavex Life Sciences Corp. announced the successful completion of enrollment in its Phase 2 clinical study of ANAVEX®3-71 for the treatment of schizophrenia (ANAVEX3-71-SZ-001). The study has fully enrolled a total of 71 participants, with 16 participants in Part A and 55 participants in Part B.
Part A of the study, which investigated multiple ascending doses, has already been completed and previously reported encouraging preliminary safety and electroencephalography (EEG) biomarker results. Part B, with its larger participant count and longer treatment duration, is designed to provide more comprehensive clinical and biomarker data on the efficacy and safety of ANAVEX®3-71.
The company expects to report top-line data from the full study in the second half of 2025. This milestone is significant as there is a substantial unmet medical need for a drug that can effectively address all symptom domains of schizophrenia without the side effects of standard antipsychotics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.